KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Intangibles (2016 - 2025)

Biogen has reported Intangibles over the past 17 years, most recently at $9.2 billion for Q4 2025.

  • Quarterly results put Intangibles at $9.2 billion for Q4 2025, down 5.29% from a year ago — trailing twelve months through Dec 2025 was $9.2 billion (down 5.29% YoY), and the annual figure for FY2025 was $9.2 billion, down 5.29%.
  • Intangibles for Q4 2025 was $9.2 billion at Biogen, down from $9.3 billion in the prior quarter.
  • Over the last five years, Intangibles for BIIB hit a ceiling of $9.8 billion in Q3 2024 and a floor of $100.0 million in Q3 2023.
  • Median Intangibles over the past 5 years was $2.3 billion (2021), compared with a mean of $5.0 billion.
  • Biggest five-year swings in Intangibles: plummeted 95.02% in 2023 and later skyrocketed 9705.5% in 2024.
  • Biogen's Intangibles stood at $2.2 billion in 2021, then decreased by 16.71% to $1.9 billion in 2022, then soared by 352.03% to $8.4 billion in 2023, then grew by 15.88% to $9.7 billion in 2024, then dropped by 5.29% to $9.2 billion in 2025.
  • The last three reported values for Intangibles were $9.2 billion (Q4 2025), $9.3 billion (Q3 2025), and $9.5 billion (Q2 2025) per Business Quant data.